Alzheimer’s disease (AD) is increasingly recognized as a disorder not only of cortical amyloid-β and tau deposition, but also of upstream neuromodulatory and clearance systems that shape when and where pathology emerges. Among these, the locus coeruleus (LC) noradrenergic nucleus and the brain’s perivascular “glymphatic” network have attracted particular attention. In this review, we synthesize converging evidence that positions the LC–glymphatic interplay as a mechanistically relevant “axis” in AD, and evaluate two magnetic resonance imaging (MRI)-based proxies of this axis: neuromelanin-sensitive LC imaging and diffusion tensor image analysis along the perivascular space (DTI-ALPS). We first summarize neuropathological and experimental data demonstrating that the LC is an early and vulnerable tau node whose degeneration perturbs synaptic plasticity, neuroinflammation, sleep–wake regulation and vascular dynamics. The evidence base spans post-mortem neuropathology, animal mechanistic studies, and predominantly cross-sectional human MRI/PET observational cohorts, with fewer longitudinal studies and very limited interventional imaging datasets. We then review acquisition protocols, reliability and clinical findings for LC neuromelanin MRI, highlighting robust associations with cognitive performance and downstream tau burden. In parallel, we describe the physiological basis and methodological implementation of DTI-ALPS as an indirect marker of perivascular CSF–interstitial fluid transport, and collate studies linking reduced ALPS indices to amyloid/tau biomarkers, small vessel disease and cognitive decline. Integrating these literatures, we propose an in-vivo “LC–glymphatic axis” framework in which LC degeneration and impaired perivascular transport co-evolve and jointly influence AD risk and progression. We discuss how this framework can inform biomarker development, risk stratification and trial enrichment, and outline neuromodulatory strategies—such as transcutaneous vagus nerve stimulation and closed-loop slow-wave sleep enhancement—that could be used to experimentally engage this axis with LC MRI and ALPS as mechanism-proximal endpoints. Finally, we critically appraise methodological limitations, conceptual uncertainties and key gaps in longitudinal, multimodal and interventional evidence. Overall, imaging the LC–glymphatic axis offers a promising route to move beyond purely cortical markers and to test whether targeting upstream neuromodulation and clearance can contribute to genuine disease modification in AD.
- Article type
- Year
- Co-author
Open Access
Review
Issue
Open Access
Topical Review
Issue
Three-dimensional (3D) printing technology has opened a new paradigm to controllably and reproducibly fabricate bioengineered neural constructs for potential applications in repairing injured nervous tissues or producing in vitro nervous tissue models. However, the complexity of nervous tissues poses great challenges to 3D-printed bioengineered analogues, which should possess diverse architectural/chemical/electrical functionalities to resemble the native growth microenvironments for functional neural regeneration. In this work, we provide a state-of-the-art review of the latest development of 3D printing for bioengineered neural constructs. Various 3D printing techniques for neural tissue-engineered scaffolds or living cell-laden constructs are summarized and compared in terms of their unique advantages. We highlight the advanced strategies by integrating topographical, biochemical and electroactive cues inside 3D-printed neural constructs to replicate in vivo-like microenvironment for functional neural regeneration. The typical applications of 3D-printed bioengineered constructs for in vivo repair of injured nervous tissues, bio-electronics interfacing with native nervous system, neural-on-chips as well as brain-like tissue models are demonstrated. The challenges and future outlook associated with 3D printing for functional neural constructs in various categories are discussed.
京公网安备11010802044758号